Cutting Through the Noise on Microbiome Diversity

There’s a lot of well-meaning, but often oversimplified, conversation online about microbiome diversity. The reality is more nuanced. The human gut microbiome is an extraordinarily complex ecosystem, shaped by thousands of bacterial species. Your microbial “fingerprint” is as unique as you are, and two people can display very different gut profiles due to diet, cultural background, ethnicity, or environment, yet both are perfectly healthy. In other words, there is no single ideal microbiome everyone should try to achieve.

What we do know is that a gut ecosystem with a broad range of bacterial groups tends to support multiple physiological functions. It contributes to digestion, immune communication, barrier integrity, and production of key metabolites. Diet plays an important role: greater intake of fruits and vegetables is generally associated with higher diversity, whereas frequent consumption of sugary drinks tends to correlate with lower diversity. A more diverse ecosystem is typically more resilient, meaning it can better withstand stressors such as antibiotics, illness, and abrupt dietary changes.

Probiotics support this ecosystem functionally rather than attempting to overwrite it structurally. They don’t make your microbiome look like someone else’s. Instead, well metabolites can reinforce beneficial functions, help maintain barrier integrity, produce relevant metabolites, and encourage a favorable balance where appropriate. The most accurate way to think about probiotics is as tools for stability and resilience, complementary to diet and lifestyle, rather than as a shortcut to “more diversity.”

Why “not all probiotics are created equal” is more than a slogan

Quality and effectiveness begin at the strain level and continue through manufacturing and delivery. Many conversations still focus on species, but real-world benefits are strain specific. Two strains within the same species can behave differently, just as two dogs of the same breed can have distinct temperaments and abilities. Clinical documentation is tied to the exact, named strain, not the generic species label.

Cerebiome® is a concrete example: a combination of L. helveticus Rosell®52 and B. longum Rosell®175 that has been specifically studied for gut-brain axis support and mental wellbeing. If you want the benefits shown in the research, you need those exact strains at the right dose and format. Substituting a random L. helveticus with a random B. longum does not transfer the evidence and shouldn’t be marketed as if it does.

Equally critical is the production journey. By definition, probiotics are live microorganisms, and “live” is the operational challenge. Between fermentation, drying, encapsulation, packaging, storage, transport, and gastric passage, strains face moisture, oxygen, heat, and acidity. If the product isn’t carefully produced and protected, viability can decline before it reaches the consumer, let alone the gut. This is where end-to-end quality systems matter. With 90 years of knowhow, Lallemand Health Solutions controls the process from lab to shelf, operating under rigorous quality standards and accreditations, and ensuring that clinically documented strains are delivered consistently and remain viable through end of shelf life.

From lab to label: the probiotic journey

The story of a high-quality probiotic starts long before the capsule. At the Rosell® Institute for Microbiome and Probiotics, discovery platforms screen strains in vitro and in vivo to establish safety and investigate mechanisms of action with advanced technologies and models. Only the most promising candidates move forward to clinical evaluation. Well-designed trials, sponsor, investigator, or client-initiated, validate which strain delivers which benefit, in which population, and at what dose. Once evidence is established, bioprocess experts optimize fermentation and protect the strain through tailored delivery formats that align with target populations and use cases. The entire chain is designed to preserve viability and performance to the point of consumption.

For brands and formulators, the label is the bridge between science and trust. Practical due diligence starts with the full strain name rather than only the genus and species; this is the only way to connect the product with clinical evidence. It continues with a viability guarantee expressed as CFU at the end of shelf life, not just at manufacture, which signals that the brand is designed for stability over time for the product’s shelf life. It also includes a clearly described documented benefit that matches the strain’s research rather than vague, catchall promises. Finally, transparency is a hallmark of evidencel-ed products: brands that invest in clinically studied strains tend to say so, name them, and reference data.

Gut-brain‑ axis and mental well‑being: where the evidence is pointing

Interest in the microbiota-gut-brain axis has accelerated dramatically. Lallemand’s Rosell® Institute initiated the first clinical studies in healthy adults using Cerebiome®, a probiotic formula combining Lactobacillus helveticus Rosell®52 and Bifidobacterium longum Rosell®175 at 3 billion CFU per day. Since the early 2000s, Cerebiome® has been evaluated in ten clinical and eleven preclinical studies, highlighting eight mechanisms of action related to the gut-brain axis. Early clinical work by Diop et al. (2008) and Messaoudi et al. (2010) demonstrated benefits on stress-related gastrointestinal symptoms and occasional psychological stress in otherwise healthy adults.

The evidence base has expanded beyond stress to outcomes aligned with holistic wellbeing, including sleep quality. Among the most recent publications, Wiacek et al. (2024) and Murack et al. (2024) reported benefits related to sleep, with the preclinical work offering new mechanistic insights into sleep architecture modulation and depressive-like behaviors in adolescent mice in sleep-disrupted conditions. A proof-of-concept study by Kassem et al. (2025) explored improvements in circadian rhythm, perceived stress, and aspects of skin health, supporting an “in-and-out” wellbeing perspective. In parallel, the wider scientific community has been prolific: more than 1,600 papers on the microbiome-gut-brain axis were published in 2024. A recent review by Slykerman et al. (2025) identified the L. helveticus Rosell®52 and B. longum Rosell®175 combination, Cerebiome®, as the most evidence-supported probiotic formulation for mental health. Together, these findings clarify how specific strains can modulate physiological and psychological responses to occasional stress, enabling authority-approved claims in certain markets, subject to local regulations.

Personalization that works today

Every person’s microbiota is distinctive; there is no universal “ideal.” However, research shows that in certain conditions, such as intestinal diseases or obesity, the microbiota can display reduced abundance and diversity, with a loss of functions that normally support metabolic balance. Personalization is rising to meet this reality, but there are two practical lanes for brands.

The first is composition-based personalization using microbiota tests. While promising, the science isn’t yet mature enough to deliver precise, strain-level recommendations for most healthy consumers solely on the basis of a snapshot of composition. The second approach is needs-based personalization, which is both actionable and evidence aligned today. Here, brands connect clinically documented strains to common health goals in healthy populations, such as digestive comfort, stress management, immune support, or sleep quality, and design programs and delivery forms accordingly. Increasingly, companies offer regimen personalization, such as curated daily packs that combine targeted capsules for multiple goals over thirty days. When these programs are built on documented strains, appropriate doses, and robust stability, they make personalization tangible and trustworthy.

One research-backed way to take control of gut health

Empowerment starts with awareness. The gut is often called the body’s “second brain” because it influences digestion, immune function, metabolism, mental wellbeing, and even aspects of healthy aging. Paying attention to how your gut responds to foods, stress, and daily routines is a practical first step. A balanced lifestyle, fiber-rich meals, fruits and vegetables, regular physical activity, adequate sleep, and effective stress management, creates the foundation on which probiotics can play a targeted role. Strain-specific, clinically documented formulations can support particular goals or help maintain microbial balance, but they are not a magic fix. When brands communicate this honestly and deliver rigorously on strain, dose, format, and viability, they foster outcomes consumers can feel, and trust.

Where to go next

If you’re exploring how microbiome science can translate into differentiated products, especially in areas like mental wellbeing and healthy aging, our team can help you connect the dots from evidence to market-ready innovation. Explore the science behind targeted strains and download our latest white paper on healthy aging to see how microbiome modulation and lifestyle strategies can work together for better long-term outcomes. If you want to learn more about the most documented psychobiotic for the microbiome gut-brain axis, visit Cerebiome dedicated page

Watch the Strong on Health podcast episode here: